Biogen Idec researchers identify potential new pathway in rheumatoid arthritis disease process
Discovered by Biogen Idec and University of Geneva scientists, TWEAK belongs to a family of molecules called tumor necrosis factor (TNF) that plays an important role in normal immune system and inflammatory responses. TNF-inhibiting therapies are currently used to treat a number of diseases including RA, a chronic, autoimmune disease that causes inflammation and swelling of the joints and the surrounding synovial tissue, resulting in progressive damage to the cartilage and bone.
TWEAK stimulates blood vessel growth (angiogenesis) and production of inflammatory proteins called cytokines and chemokines. The published studies found that TWEAK promotes a number of events that are hallmarks of rheumatoid arthritis, including joint inflammation and synovial angiogenesis (blood vessel growth in joints).
Specifically, the Biogen Idec researchers found that TWEAK promotes joint inflammation by stimulating the production of several types of inflammatory proteins, triggers joint damage by stimulating the production of damaging metalloprotease enzymes and promoting bone breakdown, and contributes to joint tissue disease by directly promoting angiogenesis in synovial tissue. The studies also suggest that TWEAK may impede normal bone repair mechanisms.
"Our research is part of a broader effort to identify the role of the TWEAK pathway in several autoimmune diseases," added Linda Burkly, Ph.D., the TWEAK program leader at Biogen Idec.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.